Abstract 122: The Eicosanoid Analogue Cs585 Represents A First-in-class In Prevention Of Platelet Activation And Thrombosis Through Direct Activation Of The Prostacyclin Receptor

Adriana Yamaguchi(University of Michigan), Michael Holinstat(Thomas Jefferson University), Andrew D. White(University of California San Diego), Björn Dahlöf(Sahlgrenska University Hospital), Andrew Rickenberg(University of Michigan), Pooja Yalavarthi(University of Michigan), Livia Stanger(University of Michigan), Sylviane Lambert(University of Michigan)

Arteriosclerosis Thrombosis and Vascular Biology

May 1, 2023

10.1161/atvb.43.suppl_1.122

Cited by 0

Related Papers

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

|The Lancet|1998|5.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|1.6k

Nitric oxide‐induced mitochondrial fission is regulated by dynamin‐related GTPases in neurons

|The EMBO Journal|2006|649

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

|The Lancet|2010|518